| [1] |
Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial [J]. J Clin Oncol,2006,24(19): 3032-3038.
|
| [2] |
Fukushige S,Matsubara K,Yoshida M,et al. Localization of a novel v-erbB-related gene,c-erbB-2,on human chromosome 17 and its amplification in a gastric cancer cell line[J]. Mol Cell Biol,1986,6(3): 955-958.
|
| [3] |
Green AR, Barros FF, Abdel-Fatah TM, et al. HER2/ HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer [J].Breast Cancer Res Treat,2014,145(1): 33-44.
|
| [4] |
Ismaili N, Elmajjaoui S, Tahri A, et al. Trastuzumab in early breast cancer [J]. Presse Med,2013,42(7-8): 1069-1080.
|
| [5] |
Cao XZ, Xiang HL, Quan MF, et al. Inhibition of cell growth by BrMC through inactivation of Akt in HER-2/ neuoverexpressing breast cancer cells [J]. Oncol Lett, 2014,7(5): 1632-1638.
|
| [6] |
Martin HL, Smith L, Tomlinson DC, et al. Multidrug-resistant breast cancer: current perspectives [J]. Breast Cancer,2014,10(6): 1-13.
|
| [7] |
Yardley DA, Tripathy D, Brufsky AM, et al. Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER [J]. Br J Cancer, 2014, doi: 10.1038/ bjc.2014.174.
|
| [8] |
Van der Hage JA, Van de Velde CJ, Julien JP, et al.Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902 [J]. J Clin Oncol, 2001,19(22): 4224-4237.
|
| [9] |
Nitz U, Rezai M, Daubel A, et al. Surgical procedure after primary chemotherapy of breast carcinoma--an unresolved clinical problem [J]. Zentralbl Gynakol, 2000,122 (5): 248-254.
|
| [10] |
Kashiwagi S, Ishihara S, Ishii M, et al. Case of a patient with inflammatory breast cancer who responded to preoperative chemotherapy with paclitaxel plus bevacizumab and could subsequently undergo surgery [J]. Gan To Kagaku Ryoho,2013,40(12): 2384-2386.
|
| [11] |
Knuttel FM, Menezes GL, van den Bosch MA, et al. Current clinical indications for magnetic resonance imaging of the breast[J]. J Surg Oncol,2014, doi: 10.1002/jso.23655.
|
| [12] |
Prati R, Minami CA, Gornbein JA, et al. Accuracy of clinical evaluation of locally advanced breast cancer in patients receiving neoadjuvant chemotherapy [ J]. Cancer, 2009,115 (6): 1194-2202.
|
| [13] |
Kawajiri H, Takashima T, Aomatsu N, et al. Prognostic significance of pathological complete response following neoadjuvant chemotherapy for operable breast cancer [J].Oncol Lett,2014,7(3): 663-668.
|
| [14] |
Kawajiri H, Takashima T, Onoda N, et al. Efficacy and feasibility of neoadjuvant chemotherapy with FEC 100 followed by weekly paclitaxel for operable breast cancer[J]. Oncol Lett,2012,4(4): 612-616.
|
| [15] |
Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial[J].Lancet Oncol,2013,14(8): 741-748.
|
| [16] |
Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer(NeoALTTO): a randomised, open-label, multicentre, phase 3 trial [J]. Lancet,2012,379(9816): 633-640.
|
| [17] |
Buzdar AU, Suman VJ, Meric-Bernstam F, et al.Fluorouracil, epirubicin, and cyclophosphamide (FEC-75)followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised,controlled,phase 3 trial [J].Lancet Oncol,2013,14(13): 1317-1325.
|
| [18] |
谢奕彪,边莉,王涛,等. 曲妥珠单抗联合蒽环类及紫杉类方案在乳腺癌新辅助化疗中安全性的观察和分析[J]. 中国癌症杂志,2012,22(5): 396-398.
|
| [19] |
陈伟财, 王敏, 吴恢升,等. 新辅助化疗联合曲妥珠单抗对HER-2 过表达乳腺癌的疗效观察[J]. 中国普通外科杂志,2012,21(5): 503-507.
|
| [20] |
Ro J, Park IH, Lee KS, et al. Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy [J]. J Clin Oncol, 2010, 28 (16): 2705-2711.
|
| [21] |
Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomized controlled superiority trial with a parallel HER2-negative cohort[J]. Lancet Oncol,2014,15(6): 640-647.
|
| [22] |
Pinto AC, Ades F, de Azambuja E, et al. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies [J]. Breast, 2013, 22 Suppl 2: S152-155.
|
| [23] |
Buzdar AU,Ibrahim NK,Francis D,et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer[J]. Clin Oncol,2005,23(16): 3676-3685.
|
| [24] |
Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study [ J]. Clin Oncol, 2010, 28 (12): 2024-2031.
|
| [25] |
Dawood S, Resetkova E, Gonzalez-Angulo AM. Trastuzumab administration associated with change in HER2 status[J]. Clin Breast Cancer,2008,8(4): 366-369.
|
| [26] |
Chang HR. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer[J]. Cancer, 2010,116(12): 2856-2867.
|
| [27] |
Lawicki S, Będkowska GE, Gacuta-Szumarska E, et al. The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors[J]. J Ovarian Res,2013,6(1): 45.
|
| [28] |
Yardley DA, Raefsky E, Castillo R, et al. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2 + breast cancer [J]. Clin Breast Cancer,2011,11(5): 297-305.
|
| [29] |
Azim HA Jr,Agbor-Tarh D,Bradbury I,et al. Pattern of rash,diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial [J]. Clin Oncol, 2013,31(36): 4504-4511.
|
| [30] |
Dent S, Oyan B, Honig A, et al. HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials[J].Cancer Treat Rev,2013,39(6): 622-631.
|